Catalent Pharma Expands in China - Acquires majority stake in Zhejiang Jiang Yuan Tang and forms JV with ShangPharma to provide supplies for Clinical trials

Catalent Pharma Solutions, a New Jersey company, announced two transactions that will increase its presence in China. First, Catalent will acquire majority share of Zhejiang Jiang Yuan Tang Biotechnology Co., a Haining maker of nutritional softgel products for China and other Asia Pacific markets. And second, Catalent formed a JV with ShangPharma that will provide supplies of drugs for clinical trials. Catalent is involved in drug delivery systems, including soft gels, and it also provides clinical and commercial supplies of drugs world-wide.